RxDoctor Payments Data

Chris Oneil, DO

Family Medicine · Bloomsburg, PANPI 1154313450

Payments from drug & device makers

$10,778in general payments, 2019–2025

Across 651 payments — averaging $16.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AbbVie$2K
  • AstraZeneca$1K
  • Pfizer$858
  • Amgen$764
  • Boehringer Ingelheim$677
  • plus $4K from 35 others

What the payments were for

  • Food & beverage$10,756100%
  • Education$220%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,778 in reported general payments places this provider in the 90th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$662,281
Medicare patients
1,019
Services billed
9,866

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban240$220,011
JardianceEmpagliflozin136$140,328
OzempicSemaglutide55$86,023
FarxigaDapagliflozin Propanediol35$54,721
TradjentaLinagliptin59$50,242
JanuviaSitagliptin Phosphate44$46,259
XareltoRivaroxaban29$35,556
TrulicityDulaglutide20$31,255
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$23,944
WegovySemaglutide12$21,931
VraylarCariprazine Hcl15$20,964
Tresiba Flextouch U-200Insulin Degludec20$19,904
Breztri AerosphereBudesonide/Glycopyr/Formoterol25$17,197
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog26$15,566
MounjaroTirzepatide13$15,024

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$858$220,011240 claims
Boehringer IngelheimJardiance, Tradjenta$677$190,570195 claims
Novo NordiskOzempic, Wegovy$1,877$107,95467 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,130$71,91860 claims
Lilly USA, LLCTrulicity, Mounjaro$671$46,27833 claims
MerckJanuvia$394$46,25944 claims
Johnson & JohnsonXarelto$165$35,55629 claims
AbbVieVraylar, Linzess$1,518$33,06231 claims
GSKTrelegy Ellipta, Breo Ellipta$231$29,88736 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$148$8,34611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Bloomsburg

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →